product summary
Loading...
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
antibody
product name :
p53 Antibody Cocktail
catalog :
MA5-14067
quantity :
500 uL
price :
US 520.00
clonality :
monoclonal
host :
mouse
conjugate :
nonconjugated
clone name :
DO-7, BP53-12
reactivity :
human, mouse, rhesus macaque
application :
western blot, ELISA, immunohistochemistry, immunocytochemistry, immunoprecipitation, immunohistochemistry - paraffin section
more info or order :
citations: 134
| Published Application/Species/Sample/Dilution | Reference |
|---|---|
| |
| |
| |
| |
| |
| |
| |
| |
| Akrish S, Ben Izhak O, Sabo E, Rachmiel A. Oral squamous cell carcinoma associated with proliferative verrucous leukoplakia compared with conventional squamous cell carcinoma--a clinical, histologic and immunohistochemical study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;119:318-25 pubmed publisher
|
| |
| |
| |
| |
| |
| Zhao Z, Lin L, Liang A, Li H, Zhu Y. UNC5H4-induced apoptosis in non-small cell lung cancer is not dependent on p53 status only. Oncol Lett. 2013;6:1363-1369 pubmed
|
| |
| Bakry O, Hammam M, Abdel Wahed M. Vitiligo: is it grace or curse?. Acta Dermatovenerol Croat. 2013;21:71-9 pubmed
|
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| Oka Y, Yamauchi M, Suzuki M, Yamashita S, Suzuki K. Persistence and dynamics of DNA damage signal amplification determined by microcolony formation and live-cell imaging. J Radiat Res. 2011;52:766-74 pubmed
|
| |
| Arik D, Kulacoglu S. P53, bcl-2, and nm23 expressions in serous ovarian tumors: correlation with the clinical and histopathological parameters. Turk Patoloji Derg. 2011;27:38-45 pubmed
|
| |
| |
| |
| |
| Angiero F, Gatta L, Seramondi R, Berenzi A, Benetti A, Magistro S, et al. Frequency and role of HPV in the progression of epithelial dysplasia to oral cancer. Anticancer Res. 2010;30:3435-40 pubmed
|
| |
| |
| |
| |
| |
| Sarafoleanu D, Postelnicu V, Iosif C, Manea C, Sarafoleanu C. The role of p53, PCNA and Ki-67 as outcome predictors in the treatment of laryngeal cancer. J Med Life. 2009;2:219-26 pubmed
|
| |
| Angiero F, Farronato G, Dessy E, Magistro S, Seramondi R, Farronato D, et al. Evaluation of the cytotoxic and genotoxic effects of orthodontic bonding adhesives upon human gingival papillae through immunohistochemical expression of p53, p63 and p16. Anticancer Res. 2009;29:3983-7 pubmed
|
| |
| |
| |
| |
| |
| Jung I, Gurzu S, Raica M, Cimpean A, Szentirmay Z. The differences between the endothelial area marked with CD31 and CD105 in colorectal carcinomas by computer-assisted morphometrical analysis. Rom J Morphol Embryol. 2009;50:239-43 pubmed
|
| Thant A, Wu Y, Lee J, Mishra D, Garcia H, Koeffler H, et al. Role of caspases in 5-FU and selenium-induced growth inhibition of colorectal cancer cells. Anticancer Res. 2008;28:3579-92 pubmed
|
| Angiero F, Berenzi A, Benetti A, Rossi E, Del Sordo R, Sidoni A, et al. Expression of p16, p53 and Ki-67 proteins in the progression of epithelial dysplasia of the oral cavity. Anticancer Res. 2008;28:2535-9 pubmed
|
| |
| |
| |
| |
| Barbareschi M, Buttitta F, Felicioni L, Cotrupi S, Barassi F, Del Grammastro M, et al. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res. 2007;13:6064-9 pubmed
|
| Melck A, Masoudi H, Griffith O, Rajput A, Wilkins G, Bugis S, et al. Cell cycle regulators show diagnostic and prognostic utility for differentiated thyroid cancer. Ann Surg Oncol. 2007;14:3403-11 pubmed
|
| Erdamar S, Ucaryilmaz E, Demir G, Karahasanoglu T, Dogusoy G, Dirican A, et al. Importance of MutL homologue MLH1 and MutS homologue MSH2 expression in Turkish patients with sporadic colorectal cancer. World J Gastroenterol. 2007;13:4437-44 pubmed
|
| Koch B, Baul T, Chatterjee A. Cell proliferation inhibition and antitumor activity of novel alkyl series of diorganotin(IV) compounds. J Appl Toxicol. 2008;28:430-8 pubmed
|
| Gurzu S, Jung J, Mezei T, Pávai Z. The correlation between the immunostains for p53 and Ki67 with bcl-2 expression and classical prognostic factors in colorectal carcinomas. Rom J Morphol Embryol. 2007;48:95-9 pubmed
|
| Arany P, Flanders K, DeGraff W, Cook J, Mitchell J, Roberts A. Absence of Smad3 confers radioprotection through modulation of ERK-MAPK in primary dermal fibroblasts. J Dermatol Sci. 2007;48:35-42 pubmed
|
| Giordano G, D Adda T, Gnetti L, Merisio C, Raboni S. Transitional cell carcinoma of the endometrium associated with benign ovarian brenner tumor: a case report with immunohistochemistry molecular analysis and a review of the literature. Int J Gynecol Pathol. 2007;26:298-304 pubmed
|
| Giordano G, D Adda T, Gnetti L, Merisio C, Gabrielli M, Melpignano M. Villoglandular adenocarcinoma of the cervix: two new cases with morphological and molecular study. Int J Gynecol Pathol. 2007;26:199-204 pubmed
|
| Rossner P, Binkova B, Milcova A, Solansky I, Zidzik J, Lyubomirova K, et al. Air pollution by carcinogenic PAHs and plasma levels of p53 and p21(WAF1) proteins. Mutat Res. 2007;620:34-40 pubmed
|
| Kerley Hamilton J, Pike A, Hutchinson J, Freemantle S, Spinella M. The direct p53 target gene, FLJ11259/DRAM, is a member of a novel family of transmembrane proteins. Biochim Biophys Acta. 2007;1769:209-19 pubmed
|
| Nadasi E, Anga B, Sandor J, Megyesi J, Kelemen D, Mottolese M, et al. Prognostic factors in Hungarian breast cancer patients. Anticancer Res. 2007;27:279-82 pubmed
|
| Vardar E, Gunlusoy B, Arslan M, Kececi S. Myointimoma of the glans penis. Pathol Int. 2007;57:158-61 pubmed
|
| Uberti D, Ferrari Toninelli G, Bonini S, Sarnico I, Benarese M, Pizzi M, et al. Blockade of the tumor necrosis factor-related apoptosis inducing ligand death receptor DR5 prevents beta-amyloid neurotoxicity. Neuropsychopharmacology. 2007;32:872-80 pubmed
|
| Schumacher G, Scheunert S, Rueggeberg A, Bachem M, Nussler A, Spinelli A, et al. A very low toxic agent induces apoptosis and reduces growth of human hepatocellular carcinoma cells. J Gastroenterol Hepatol. 2006;21:1207-12 pubmed
|
| Akyurek N, Memis L, Ekinci O, Kokturk N, Ozturk C. Survivin expression in pre-invasive lesions and non-small cell lung carcinoma. Virchows Arch. 2006;449:164-70 pubmed
|
| Aldovini D, Demichelis F, Doglioni C, Di Vizio D, Galligioni E, Brugnara S, et al. M-CAM expression as marker of poor prognosis in epithelial ovarian cancer. Int J Cancer. 2006;119:1920-6 pubmed
|
| Bulut S, Uslu H, Ozdemir B, Bulut O. Expression of caspase-3, p53 and Bcl-2 in generalized aggressive periodontitis. Head Face Med. 2006;2:17 pubmed
|
| Ardeleanu C, Ceausu M, Butur G, Grămadă Z, Danaila L, Hălălău F, et al. p53 protein and bcl-2 expression in glioblastomas. Pathological correlations in a comprehensive series. Rom J Morphol Embryol. 2005;46:275-8 pubmed
|
| Lee M, Suh C, Li Z. Clinicopathological significance of maspin expression in breast cancer. J Korean Med Sci. 2006;21:309-14 pubmed
|
| Yang Y, Hsu Y, Wu C, Chen H, Chang M. Silencing of astrin induces the p53-dependent apoptosis by suppression of HPV18 E6 expression and sensitizes cells to paclitaxel treatment in HeLa cells. Biochem Biophys Res Commun. 2006;343:428-34 pubmed
|
| Coll Mulet L, Iglesias Serret D, Santidrian A, Cosialls A, de Frias M, Castaño E, et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood. 2006;107:4109-14 pubmed
|
| Ray S, Chatterjee A. Influence of endogenous glutathione level on X-ray induced cell cycle delay in human lymphocytes. Cell Prolif. 2006;39:37-47 pubmed
|
| Schrier B, Vriesema J, Witjes J, Kiemeney L, Schalken J. The predictive value of p53, p27(kip1), and alpha-catenin for progression in superficial bladder carcinoma. Eur Urol. 2006;50:76-82 pubmed
|
| Osada M, Park H, Nagakawa Y, Begum S, Yamashita K, Wu G, et al. A novel response element confers p63- and p73-specific activation of the WNT4 promoter. Biochem Biophys Res Commun. 2006;339:1120-8 pubmed
|
| Yilmazbayhan D, Ates L, Dilege S, Gulluoglu M, Tanju S, Kalayci G. Pulmonary large cell carcinoma with rhabdoid phenotype. Ann Diagn Pathol. 2005;9:223-6 pubmed
|
| Berghmans T, Mascaux C, Martin B, Ninane V, Sculier J. Prognostic role of p53 in stage III non-small cell lung cancer. Anticancer Res. 2005;25:2385-9 pubmed
|
| Akhan S, Yavuz E, Tecer A, Iyibozkurt C, Topuz S, Tuzlali S, et al. The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study. Gynecol Oncol. 2005;99:36-42 pubmed
|
| Osada M, Nagakawa Y, Park H, Yamashita K, Wu G, Kim M, et al. p63-specific activation of the BPAG-1e promoter. J Invest Dermatol. 2005;125:52-60 pubmed
|
| Yamauchi M, Suzuki K, Kodama S, Watanabe M. Abnormal stability of wild-type p53 protein in a human lung carcinoma cell line. Biochem Biophys Res Commun. 2005;330:483-8 pubmed
|
| Torkin R, Lavoie J, Kaplan D, Yeger H. Induction of caspase-dependent, p53-mediated apoptosis by apigenin in human neuroblastoma. Mol Cancer Ther. 2005;4:1-11 pubmed
|
Li Z, Day C, Yang J, Tsai W, Lozano G, Shih H, et al. Adenoviral E1A targets Mdm4 to stabilize tumor suppressor p53. Cancer Res. 2004;64:9080-5 pubmed
| |
Milne A, Carvalho R, van Rees B, van Lanschot J, Offerhaus G, Weterman M. Do collision tumors of the gastroesophageal junction exist? A molecular analysis. Am J Surg Pathol. 2004;28:1492-8 pubmed
| |
Marchioni D, Monzani D, Rossi G, Rivasi F, Presutti L. Breast carcinoma metastases in paranasal sinuses, a rare occurrence mimicking a primary nasal malignancy. case report. Acta Otorhinolaryngol Ital. 2004;24:87-91 pubmed
| |
Fomenkov A, Zangen R, Huang Y, Osada M, Guo Z, Fomenkov T, et al. RACK1 and stratifin target DeltaNp63alpha for a proteasome degradation in head and neck squamous cell carcinoma cells upon DNA damage. Cell Cycle. 2004;3:1285-95 pubmed
| |
Yamauchi M, Suzuki K, Kodama S, Watanabe M. Stabilization of alanine substituted p53 protein at Ser15, Thr18, and Ser20 in response to ionizing radiation. Biochem Biophys Res Commun. 2004;323:906-11 pubmed
| |
Tokumaru Y, Yamashita K, Osada M, Nomoto S, Sun D, Xiao Y, et al. Inverse correlation between cyclin A1 hypermethylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing. Cancer Res. 2004;64:5982-7 pubmed
| |
Tulunay O, Gogus C, Baltaci S, Bulut S. Clear cell adenocarcinoma of the tunica vaginalis of the testis with an adjacent uterus-like tissue. Pathol Int. 2004;54:641-7 pubmed
| |
Caricasole A, Copani A, Caraci F, Aronica E, Rozemuller A, Caruso A, et al. Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain. J Neurosci. 2004;24:6021-7 pubmed
| |
Tabs S, Avci O. Induction of the differentiation and apoptosis of tumor cells in vivo with efficiency and selectivity. Eur J Dermatol. 2004;14:96-102 pubmed
| |
Meert A, Martin B, Verdebout J, Paesmans M, Berghmans T, Ninane V, et al. Correlation of different markers (p53, EGF-R, c-erbB-2, Ki-67) expression in the diagnostic biopsies and the corresponding resected tumors in non-small cell lung cancer. Lung Cancer. 2004;44:295-301 pubmed
| |
Jayasurya R, Francis G, Kannan S, Lekshminarayanan K, Nalinakumari K, Abraham T, et al. p53, p16 and cyclin D1: molecular determinants of radiotherapy treatment response in oral carcinoma. Int J Cancer. 2004;109:710-6 pubmed
| |
Roberts K, Bhatia K, Stanton P, Lord R. Proteomic analysis of selected prognostic factors of breast cancer. Proteomics. 2004;4:784-92 pubmed
| |
Deveci M, Deveci G. Altered distribution of metaplastic Paneth, gastrin and pancreatic acinar cells in atrophic gastritic mucosa with endocrine cell lesions. Tohoku J Exp Med. 2004;202:13-22 pubmed
| |
Alami J, Williams B, Yeger H. Derivation and characterization of a Wilms' tumour cell line, WiT 49. Int J Cancer. 2003;107:365-74 pubmed
| |
Schwartz J, Muscat J, Baker V, Larios E, Stephenson G, Guo W, et al. Oral cytology assessment by flow cytometry of DNA adducts, aneuploidy, proliferation and apoptosis shows differences between smokers and non-smokers. Oral Oncol. 2003;39:842-54 pubmed
| |
Hamada N, Kodama S, Suzuki K, Watanabe M. Gap junctional intercellular communication and cellular response to heat stress. Carcinogenesis. 2003;24:1723-8 pubmed
| |
Deliveliotis C, Skolarikos A, Karayannis A, Tzelepis V, Trakas N, Alargof E, et al. The prognostic value of p53 and DNA ploidy following radical prostatectomy. World J Urol. 2003;21:171-6 pubmed
| |
Kumpawat K, Deb S, Ray S, Chatterjee A. Genotoxic effect of raw betel-nut extract in relation to endogenous glutathione levels and its mechanism of action in mammalian cells. Mutat Res. 2003;538:1-12 pubmed
| |
Mascaux C, Martin B, Verdebout J, Meert A, Ninane V, Sculier J. Fragile histidine triad protein expression in nonsmall cell lung cancer and correlation with Ki-67 and with p53. Eur Respir J. 2003;21:753-8 pubmed
| |
Campas C, Dalmau M, Montaner B, Barragan M, Bellosillo B, Colomer D, et al. Prodigiosin induces apoptosis of B and T cells from B-cell chronic lymphocytic leukemia. Leukemia. 2003;17:746-50 pubmed
| |
Campas C, Lopez J, Santidrian A, Barragan M, Bellosillo B, Colomer D, et al. Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes. Blood. 2003;101:3674-80 pubmed
| |
DiRenzo J, Signoretti S, Nakamura N, Rivera Gonzalez R, Sellers W, Loda M, et al. Growth factor requirements and basal phenotype of an immortalized mammary epithelial cell line. Cancer Res. 2002;62:89-98 pubmed
| |
Lee H, Kim J, Ha S, Roh K, Seo E, Park W, et al. p53 gene mutations in Bowen's disease in Koreans: clustering in exon 5 and multiple mutations. Cancer Lett. 2000;158:27-33 pubmed
|
product information
Product Type :
Antibody
Product Name :
p53 Antibody Cocktail
Catalog # :
MA5-14067
Quantity :
500 uL
Price :
US 520.00
Clonality :
Cocktail
Purity :
protein A
Host :
Mouse
Reactivity :
Human, Mouse, Rhesus Monkey
Applications :
ChIP Assay: 1-3 ug x 10^6 cells, Immunohistochemistry (Paraffin): 1-2 ug/mL, Immunoprecipitation: 2 ug/mL, Western Blot: 0.5-1.0 ug/mL
Species :
Human, Mouse, Rhesus Monkey
Clone :
DO-7, BP53-12
Isotype :
IgG2a/IgG2b
Storage :
4 C
Description :
The tumor suppressor protein, p53, is a sequence specific transcription factor that is activated by cellular stress. p53 mediates cell cycle arrest or apoptosis in response to DNA damage or starvation for pyrimidine nucleotides. p53 is up-regulated in response to stress signals and stimulated to activate transcription of specific genes, resulting in expression of p21waf1 and other proteins involved in G1 or G2/M arrest. The structure of p53 comprises an N-terminal transactivation domain, a central DNA-binding domain, an oligomerisation domain, and a C-terminal regulatory domain. There are various phosphorylation sites on p53, of which the phosphorylation at Ser15 is important for p53 activation and stabilization. p53 has been characterized to play a role in blocking the proliferative action of damaged cells and act as an anticancer agent. Phosphorylation of Ser392 in p53 has been shown to associate with the formation of human tumors. In addition, p53 has also been linked to the effects of aging and oxidative stress and an increase in p53 has been linked to deficits in LTP (Long Term Potentiation) in learning and memory. p53 is found in very low levels in normal cells, however, in a variety of transformed cell lines, it is expressed in high amounts, and believed to contribute to transformation and malignancy. Mutants of p53 that frequently occur in a number of different human cancers fail to bind the consensus DNA binding site, and cause the loss of tumor suppressor activity. Alterations of the TP53 gene occur not only as somatic mutations in human malignancies, but also as germline mutations in some cancer-prone families such as Li-Fraumeni syndrome.
Immunogen :
Recombinant human p53 protein
Format :
Liquid
Applications w/Dilutions :
ChIP Assay: 1-3 ug x 10^6 cells, Immunohistochemistry (Paraffin): 1-2 ug/mL, Immunoprecipitation: 2 ug/mL, Western Blot: 0.5-1.0 ug/mL
Aliases :
Antigen NY-CO-13; bbl; BCC7; bfy; bhy; cellular tumor antigen p53; Cys 51 Stop; EGK_08142; FLJ92943; HGNC11998; I79_002739; LFS1; Li-Fraumeni syndrome; mutant p53; mutant tumor protein 53; OTTMUSP00000006194; p44; p53; p53 cellular tumor antigen; p53 protein; p53 tumor suppressor; p53 tumor suppressor phosphoprotein; phosphoprotein p53; Tp53; tp53.L; transformation related protein 53; transformation-related protein 53; Trp248; Trp53; tumor protein 53; tumor protein p53; tumor protein p53 (Li-Fraumeni syndrome); tumor protein p53 L homeolog; tumor suppressor p53; tumor suppressor p53 phosphoprotein; tumor suppressor protein p53; tumor supressor p53; Tumour Protein p53; XELAEV_180196761mg; Xp53; Xrel3
more info or order :
company information
Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com81 Wyman Street
Waltham, MA USA 02451
800-678-5599
headquarters: USA
related products
browse more products
questions and comments